Login to Your Account



Merck advances Oncothyreon’s cancer vaccine in NSCLC

By Michael Fitzhugh
Staff Writer

Tuesday, April 8, 2014
Oncothyreon Inc. said that Merck KGaA has started a phase III trial of its out-licensed cancer vaccine tecemotide in patients with unresectable, locally advanced stage III non-small-cell lung cancer (NSCLC). The new trial seeks to confirm an overall survival (OS) benefit for certain patients and, if successful, could magnify the potential for Merck to acquire Oncothyreon in the future.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription